Non-Invasive Patch Test | DermTech Technology

In addition to traditional biopsy methods at Danesh Dermatology, we are beginning to offer non-invasive patch test procedures using the DermTech sticker technology. The sticker biopsy provides an alternative to surgical biopsy for certain lesions that are not clearly malignant, and provides information to indicate the next steps following identifying the lesion.

What is the sticker biopsy?

The DermTech Melanoma Test is a non-invasive test that can detect high-risk melanoma lesions at their earliest stages. It uses DermTech Smart Stickers to collect skin cells from the entire surface of the lesion, without the pain of a traditional biopsy. From these cells, RNA and DNA are extracted for genomic analysis by the DermTech team. The test measures genomic markers associated with melanoma, including LINC00518 and PRAME RNA markers, as well as the TERT DNA marker. This cellular material is then preserved and sent to the DermTech Gene Lab for analysis. Overall, this test can help identify high-risk melanoma lesions before they become more serious.

Why use the sticker biopsy?

Compared to traditional excision biopsies, the DermTech Melanoma Test using Smart Stickers has several advantages. First, it is a non-invasive procedure that is painless and requires no cutting or stitching. This means that there is minimal discomfort for the patient and no risk of scarring. Additionally, traditional biopsies often require a visible lesion to be present, which can delay diagnosis and treatment. Finally, the DermTech Melanoma Test has a quicker turnaround time than traditional biopsies, as results can be delivered within days rather than weeks. These advantages make the patch sticker test an appealing option for patients in the early detection and management of melanoma.

How accurate are the results of the test?

The test has a very high performance rate, with a negative predictive value of over 99%, according to DermTech. This means that if a lesion tests negative using the test, there is a less than 1% chance that it is melanoma. In comparison, the current care pathway based on morphology has a 17% chance of misdiagnosis, according to DermTech. However, no test is perfect and patients are encouraged to continue see the dermatologist if they have concerns or if their lesions change. It is important to have regular skin checks, at least once a year, to monitor new and changing moles.